Hyppää sisältöön
Sisä-Suomen syöpäkeskus - FICAN Mid

Julkaisut

G Steven Bova – PELICAN Personalized Cancer Medicine
2020

  1. Bailey, MH, Meyerson, WU, Dursi, LJ, Wang, LB, Dong, G, Liang, WW et al.. Author Correction: Retrospective evaluation of whole exome and genome mutation calls in 746 cancer samples. Nat Commun. 2020;11 (1):6232. doi: 10.1038/s41467-020-20128-w. PubMed PMID:33257764 PubMed Central PMC7705717.
  2. Woodcock, DJ, Riabchenko, E, Taavitsainen, S, Kankainen, M, Gundem, G, Brewer, DS et al.. Prostate cancer evolution from multilineage primary to single lineage metastases with implications for liquid biopsy. Nat Commun. 2020;11 (1):5070. doi: 10.1038/s41467-020-18843-5. PubMed PMID:33033260 PubMed Central PMC7545111.
  3. Bailey, MH, Meyerson, WU, Dursi, LJ, Wang, LB, Dong, G, Liang, WW et al.. Retrospective evaluation of whole exome and genome mutation calls in 746 cancer samples. Nat Commun. 2020;11 (1):4748. doi: 10.1038/s41467-020-18151-y. PubMed PMID:32958763 PubMed Central PMC7505971.
  4. Li, CH, Prokopec, SD, Sun, RX, Yousif, F, Schmitz, N, PCAWG Tumour Subtypes and Clinical Translation et al.. Sex differences in oncogenic mutational processes. Nat Commun. 2020;11 (1):4330. doi: 10.1038/s41467-020-17359-2. PubMed PMID:32859912 PubMed Central PMC7455744.
  5. Gundem, G, Van Loo, P, Kremeyer, B, Alexandrov, LB, Tubio, JMC, Papaemmanuil, E et al.. Author Correction: The evolutionary history of lethal metastatic prostate cancer. Nature. 2020;584 (7820):E18. doi: 10.1038/s41586-020-2581-5. PubMed PMID:32728210 .
  6. PCAWG Transcriptome Core Group, Calabrese, C, Davidson, NR, Demircioğlu, D, Fonseca, NA, He, Y et al.. Genomic basis for RNA alterations in cancer. Nature. 2020;578 (7793):129-136. doi: 10.1038/s41586-020-1970-0. PubMed PMID:32025019 PubMed Central PMC7054216.
  7. Alexandrov, LB, Kim, J, Haradhvala, NJ, Huang, MN, Tian Ng, AW, Wu, Y et al.. The repertoire of mutational signatures in human cancer. Nature. 2020;578 (7793):94-101. doi: 10.1038/s41586-020-1943-3. PubMed PMID:32025018 PubMed Central PMC7054213.
  8. Rheinbay, E, Nielsen, MM, Abascal, F, Wala, JA, Shapira, O, Tiao, G et al.. Analyses of non-coding somatic drivers in 2,658 cancer whole genomes. Nature. 2020;578 (7793):102-111. doi: 10.1038/s41586-020-1965-x. PubMed PMID:32025015 PubMed Central PMC7054214.
  9. Gerstung, M, Jolly, C, Leshchiner, I, Dentro, SC, Gonzalez, S, Rosebrock, D et al.. The evolutionary history of 2,658 cancers. Nature. 2020;578 (7793):122-128. doi: 10.1038/s41586-019-1907-7. PubMed PMID:32025013 PubMed Central PMC7054212.
  10. Li, Y, Roberts, ND, Wala, JA, Shapira, O, Schumacher, SE, Kumar, K et al.. Patterns of somatic structural variation in human cancer genomes. Nature. 2020;578 (7793):112-121. doi: 10.1038/s41586-019-1913-9. PubMed PMID:32025012 PubMed Central PMC7025897.
  11. ICGC/TCGA Pan-Cancer Analysis of Whole Genomes Consortium. Pan-cancer analysis of whole genomes. Nature. 2020;578 (7793):82-93. doi: 10.1038/s41586-020-1969-6. PubMed PMID:32025007 PubMed Central PMC7025898.
  12. Cortés-Ciriano, I, Lee, JJ, Xi, R, Jain, D, Jung, YL, Yang, L et al.. Comprehensive analysis of chromothripsis in 2,658 human cancers using whole-genome sequencing. Nat Genet. 2020;52 (3):331-341. doi: 10.1038/s41588-019-0576-7. PubMed PMID:32025003 PubMed Central PMC7058534.
  13. Zapatka, M, Borozan, I, Brewer, DS, Iskar, M, Grundhoff, A, Alawi, M et al.. The landscape of viral associations in human cancers. Nat Genet. 2020;52 (3):320-330. doi: 10.1038/s41588-019-0558-9. PubMed PMID:32025001 PubMed Central PMC8076016.
  14. Akdemir, KC, Le, VT, Chandran, S, Li, Y, Verhaak, RG, Beroukhim, R et al.. Disruption of chromatin folding domains by somatic genomic rearrangements in human cancer. Nat Genet. 2020;52 (3):294-305. doi: 10.1038/s41588-019-0564-y. PubMed PMID:32024999 PubMed Central PMC7058537.
  15. Rodriguez-Martin, B, Alvarez, EG, Baez-Ortega, A, Zamora, J, Supek, F, Demeulemeester, J et al.. Pan-cancer analysis of whole genomes identifies driver rearrangements promoted by LINE-1 retrotransposition. Nat Genet. 2020;52 (3):306-319. doi: 10.1038/s41588-019-0562-0. PubMed PMID:32024998 PubMed Central PMC7058536.
  16. Yuan, Y, Ju, YS, Kim, Y, Li, J, Wang, Y, Yoon, CJ et al.. Comprehensive molecular characterization of mitochondrial genomes in human cancers. Nat Genet. 2020;52 (3):342-352. doi: 10.1038/s41588-019-0557-x. PubMed PMID:32024997 PubMed Central PMC7058535.
  17. Carlevaro-Fita, J, Lanzós, A, Feuerbach, L, Hong, C, Mas-Ponte, D, Pedersen, JS et al.. Cancer LncRNA Census reveals evidence for deep functional conservation of long noncoding RNAs in tumorigenesis. Commun Biol. 2020;3 (1):56. doi: 10.1038/s42003-019-0741-7. PubMed PMID:32024996 PubMed Central PMC7002399.
  18. Yakneen, S, Waszak, SM, PCAWG Technical Working Group, Gertz, M, Korbel, JO, PCAWG Consortium et al.. Butler enables rapid cloud-based analysis of thousands of human genomes. Nat Biotechnol. 2020;38 (3):288-292. doi: 10.1038/s41587-019-0360-3. PubMed PMID:32024987 PubMed Central PMC7062635.
  19. Reyna, MA, Haan, D, Paczkowska, M, Verbeke, LPC, Vazquez, M, Kahraman, A et al.. Pathway and network analysis of more than 2500 whole cancer genomes. Nat Commun. 2020;11 (1):729. doi: 10.1038/s41467-020-14367-0. PubMed PMID:32024854 PubMed Central PMC7002574.
  20. Jiao, W, Atwal, G, Polak, P, Karlic, R, Cuppen, E, PCAWG Tumor Subtypes and Clinical Translation Working Group et al.. A deep learning system accurately classifies primary and metastatic cancers using passenger mutation patterns. Nat Commun. 2020;11 (1):728. doi: 10.1038/s41467-019-13825-8. PubMed PMID:32024849 PubMed Central PMC7002586.
  21. Paczkowska, M, Barenboim, J, Sintupisut, N, Fox, NS, Zhu, H, Abd-Rabbo, D et al.. Integrative pathway enrichment analysis of multivariate omics data. Nat Commun. 2020;11 (1):735. doi: 10.1038/s41467-019-13983-9. PubMed PMID:32024846 PubMed Central PMC7002665.
  22. Cmero, M, Yuan, K, Ong, CS, Schröder, J, PCAWG Evolution and Heterogeneity Working Group, Corcoran, NM et al.. Inferring structural variant cancer cell fraction. Nat Commun. 2020;11 (1):730. doi: 10.1038/s41467-020-14351-8. PubMed PMID:32024845 PubMed Central PMC7002525.
  23. Rubanova, Y, Shi, R, Harrigan, CF, Li, R, Wintersinger, J, Sahin, N et al.. Reconstructing evolutionary trajectories of mutation signature activities in cancer using TrackSig. Nat Commun. 2020;11 (1):731. doi: 10.1038/s41467-020-14352-7. PubMed PMID:32024834 PubMed Central PMC7002414.
  24. Zhang, Y, Chen, F, Fonseca, NA, He, Y, Fujita, M, Nakagawa, H et al.. High-coverage whole-genome analysis of 1220 cancers reveals hundreds of genes deregulated by rearrangement-mediated cis-regulatory alterations. Nat Commun. 2020;11 (1):736. doi: 10.1038/s41467-019-13885-w. PubMed PMID:32024823 PubMed Central PMC7002524.
  25. Bhandari, V, Li, CH, Bristow, RG, Boutros, PC, PCAWG Consortium. Divergent mutational processes distinguish hypoxic and normoxic tumours. Nat Commun. 2020;11 (1):737. doi: 10.1038/s41467-019-14052-x. PubMed PMID:32024819 PubMed Central PMC7002770.
  26. Shuai, S, PCAWG Drivers and Functional Interpretation Working Group, Gallinger, S, Stein, LD, PCAWG Consortium. Combined burden and functional impact tests for cancer driver discovery using DriverPower. Nat Commun. 2020;11 (1):734. doi: 10.1038/s41467-019-13929-1. PubMed PMID:32024818 PubMed Central PMC7002750.
  27. Sieverling, L, Hong, C, Koser, SD, Ginsbach, P, Kleinheinz, K, Hutter, B et al.. Genomic footprints of activated telomere maintenance mechanisms in cancer. Nat Commun. 2020;11 (1):733. doi: 10.1038/s41467-019-13824-9. PubMed PMID:32024817 PubMed Central PMC7002710.

Search PubMed

2018

  1. Kallio, HML, Hieta, R, Latonen, L, Brofeldt, A, Annala, M, Kivinummi, K et al.. Constitutively active androgen receptor splice variants AR-V3, AR-V7 and AR-V9 are co-expressed in castration-resistant prostate cancer metastases. Br J Cancer. 2018;119 (3):347-356. doi: 10.1038/s41416-018-0172-0. PubMed PMID:29988112 PubMed Central PMC6070921.
  2. Sainio, M, Visakorpi, T, Tolonen, T, Ilvesaro, J, Bova, GS. Expression of neuroendocrine differentiation markers in lethal metastatic castration-resistant prostate cancer. Pathol Res Pract. 2018;214 (6):848-856. doi: 10.1016/j.prp.2018.04.015. PubMed PMID:29728311 .
  3. Wedge, DC, Gundem, G, Mitchell, T, Woodcock, DJ, Martincorena, I, Ghori, M et al.. Sequencing of prostate cancers identifies new cancer genes, routes of progression and drug targets. Nat Genet. 2018;50 (5):682-692. doi: 10.1038/s41588-018-0086-z. PubMed PMID:29662167 PubMed Central PMC6372064.
  4. Högnäs, G, Kivinummi, K, Kallio, HML, Hieta, R, Ruusuvuori, P, Koskenalho, A et al.. Feasibility of Prostate PAXgene Fixation for Molecular Research and Diagnostic Surgical Pathology: Comparison of Matched Fresh Frozen, FFPE, and PFPE Tissues. Am J Surg Pathol. 2018;42 (1):103-115. doi: 10.1097/PAS.0000000000000961. PubMed PMID:28984675 .

Search PubMed

Jorma Isola – Cancer biology
2020

  1. Ansere, VA, Ali-Mondal, S, Sathiaseelan, R, Garcia, DN, Isola, JVV, Henseb, JD et al.. Cellular hallmarks of aging emerge in the ovary prior to primordial follicle depletion. Mech Ageing Dev. 2021;194 :111425. doi: 10.1016/j.mad.2020.111425. PubMed PMID:33383072 PubMed Central PMC8279026.
  2. Isola, JVV, Menegazzi, G, Busanello, M, Dos Santos, SB, Agner, HSS, Sarubbi, J et al.. Differences in body temperature between black-and-white and red-and-white Holstein cows reared on a hot climate using infrared thermography. J Therm Biol. 2020;94 :102775. doi: 10.1016/j.jtherbio.2020.102775. PubMed PMID:33292972 .
  3. Popp, A, Taavela, J, Graziano, P, Parente, P, Covelli, C, Lamacchia, C et al.. A New Intraepithelial γδ T-Lymphocyte Marker for Celiac Disease Classification in Formalin-Fixed Paraffin-Embedded (FFPE) Duodenal Biopsies. Dig Dis Sci. 2021;66 (10):3352-3358. doi: 10.1007/s10620-020-06680-x. PubMed PMID:33140183 PubMed Central PMC8449760.
  4. Barbaree, BA, Reiter, ME, Hickey, CM, Strum, KM, Isola, JE, Jennings, S et al.. Effects of drought on the abundance and distribution of non-breeding shorebirds in central California, USA. PLoS One. 2020;15 (10):e0240931. doi: 10.1371/journal.pone.0240931. PubMed PMID:33085697 PubMed Central PMC7577470.
  5. Dotsenko, V, Oittinen, M, Taavela, J, Popp, A, Peräaho, M, Staff, S et al.. Genome-Wide Transcriptomic Analysis of Intestinal Mucosa in Celiac Disease Patients on a Gluten-Free Diet and Postgluten Challenge. Cell Mol Gastroenterol Hepatol. 2021;11 (1):13-32. doi: 10.1016/j.jcmgh.2020.07.010. PubMed PMID:32745639 PubMed Central PMC7593586.
  6. Byrd, KB, Lorenz, AA, Anderson, JA, Wallace, CSA, Moore-O’Leary, KA, Isola, J et al.. Quantifying drought’s influence on moist soil seed vegetation in California’s Central Valley through remote sensing. Ecol Appl. 2020;30 (7):e02153. doi: 10.1002/eap.2153. PubMed PMID:32348601 .
  7. Barok, M, Le Joncour, V, Martins, A, Isola, J, Salmikangas, M, Laakkonen, P et al.. ARX788, a novel anti-HER2 antibody-drug conjugate, shows anti-tumor effects in preclinical models of trastuzumab emtansine-resistant HER2-positive breast cancer and gastric cancer. Cancer Lett. 2020;473 :156-163. doi: 10.1016/j.canlet.2019.12.037. PubMed PMID:31904483 .
  8. Isola, JVV, Zanini, BM, Sidhom, S, Kopchick, JJ, Bartke, A, Masternak, MM et al.. 17α-Estradiol promotes ovarian aging in growth hormone receptor knockout mice, but not wild-type littermates. Exp Gerontol. 2020;129 :110769. doi: 10.1016/j.exger.2019.110769. PubMed PMID:31698046 PubMed Central PMC6911620.
  9. Valkonen, M, Isola, J, Ylinen, O, Muhonen, V, Saxlin, A, Tolonen, T et al.. Cytokeratin-Supervised Deep Learning for Automatic Recognition of Epithelial Cells in Breast Cancers Stained for ER, PR, and Ki-67. IEEE Trans Med Imaging. 2020;39 (2):534-542. doi: 10.1109/TMI.2019.2933656. PubMed PMID:31398111 .
  10. Luhtala, S, Haapaniemi, T, Staff, S, Isola, J. Fluoro-Chromogenic Labelling for Detection of MCM2 to Assess Proliferation Activity in HER2-amplified Breast Carcinomas. Appl Immunohistochem Mol Morphol. 2020;28 (3):175-186. doi: 10.1097/PAI.0000000000000716. PubMed PMID:30358612 .

Search PubMed

2019

  1. Taavela, J, Viiri, K, Popp, A, Oittinen, M, Dotsenko, V, Peräaho, M et al.. Histological, immunohistochemical and mRNA gene expression responses in coeliac disease patients challenged with gluten using PAXgene fixed paraffin-embedded duodenal biopsies. BMC Gastroenterol. 2019;19 (1):189. doi: 10.1186/s12876-019-1089-7. PubMed PMID:31730447 PubMed Central PMC6858741.
  2. Isola, JVV, Zanini, BM, Sidhom, S, Kopchick, JJ, Bartke, A, Masternak, MM et al.. 17α-Estradiol promotes ovarian aging in growth hormone receptor knockout mice, but not wild-type littermates. Exp Gerontol. 2020;129 :110769. doi: 10.1016/j.exger.2019.110769. PubMed PMID:31698046 PubMed Central PMC6911620.
  3. Lähdeaho, ML, Scheinin, M, Vuotikka, P, Taavela, J, Popp, A, Laukkarinen, J et al.. Safety and efficacy of AMG 714 in adults with coeliac disease exposed to gluten challenge: a phase 2a, randomised, double-blind, placebo-controlled study. Lancet Gastroenterol Hepatol. 2019;4 (12):948-959. doi: 10.1016/S2468-1253(19)30264-X. PubMed PMID:31494096 .
  4. Valkonen, M, Isola, J, Ylinen, O, Muhonen, V, Saxlin, A, Tolonen, T et al.. Cytokeratin-Supervised Deep Learning for Automatic Recognition of Epithelial Cells in Breast Cancers Stained for ER, PR, and Ki-67. IEEE Trans Med Imaging. 2020;39 (2):534-542. doi: 10.1109/TMI.2019.2933656. PubMed PMID:31398111 .
  5. Le Joncour, V, Martins, A, Puhka, M, Isola, J, Salmikangas, M, Laakkonen, P et al.. A Novel Anti-HER2 Antibody-Drug Conjugate XMT-1522 for HER2-Positive Breast and Gastric Cancers Resistant to Trastuzumab Emtansine. Mol Cancer Ther. 2019;18 (10):1721-1730. doi: 10.1158/1535-7163.MCT-19-0207. PubMed PMID:31292166 .
  6. Turkki, R, Byckhov, D, Lundin, M, Isola, J, Nordling, S, Kovanen, PE et al.. Breast cancer outcome prediction with tumour tissue images and machine learning. Breast Cancer Res Treat. 2019;177 (1):41-52. doi: 10.1007/s10549-019-05281-1. PubMed PMID:31119567 PubMed Central PMC6647903.
  7. Isola, JVV, Velasco Acosta, DA, Bespalhok Jacometo, C, Rincón, JAA, Silveira, PAS, Corrêa, MN et al.. Intrafollicular paraoxonase 1 activity and the steroidogenic potential of the first post-partum dominant follicle in dairy cows. Reprod Domest Anim. 2019;54 (6):924-927. doi: 10.1111/rda.13442. PubMed PMID:31004539 .

Search PubMed

2018

  1. Luhtala, S, Staff, S, Kallioniemi, A, Tanner, M, Isola, J. Clinicopathological and prognostic correlations of HER3 expression and its degradation regulators, NEDD4-1 and NRDP1, in primary breast cancer. BMC Cancer. 2018;18 (1):1045. doi: 10.1186/s12885-018-4917-1. PubMed PMID:30367623 PubMed Central PMC6204010.
  2. Helin, H, Tolonen, T, Ylinen, O, Tolonen, P, Näpänkangas, J, Isola, J et al.. Optimized JPEG 2000 Compression for Efficient Storage of Histopathological Whole-Slide Images. J Pathol Inform. 2018;9 :20. doi: 10.4103/jpi.jpi_69_17. PubMed PMID:29910969 PubMed Central PMC5989536.
  3. Barok, M, Puhka, M, Vereb, G, Szollosi, J, Isola, J, Joensuu, H et al.. Cancer-derived exosomes from HER2-positive cancer cells carry trastuzumab-emtansine into cancer cells leading to growth inhibition and caspase activation. BMC Cancer. 2018;18 (1):504. doi: 10.1186/s12885-018-4418-2. PubMed PMID:29720111 PubMed Central PMC5930687.
  4. Schaffer-Smith, D, Swenson, JJ, Reiter, ME, Isola, JE. Quantifying shorebird habitat in managed wetlands by modeling shallow water depth dynamics. Ecol Appl. 2018;28 (6):1534-1545. doi: 10.1002/eap.1732. PubMed PMID:29694689 PubMed Central PMC6123259.
  5. Koivusalo, L, Kaipia, A, Kujala, P, Isola, J, Tolonen, TT. Digital image analysis of the tissue surface areas of site-designated and bilaterally pooled prostate biopsies. Histol Histopathol. 2018;33 (4):399-405. doi: 10.14670/HH-11-940. PubMed PMID:29058306 .
  6. Luhtala, S, Staff, S, Barok, M, Tanner, M, Isola, J. Comparison of Antibodies for Immunohistochemistry-based Detection of HER3 in Breast Cancer. Appl Immunohistochem Mol Morphol. 2018;26 (3):212-219. doi: 10.1097/PAI.0000000000000406. PubMed PMID:27389555 .

Search PubMed

Anne Kallioniemi – Cancer Genomics
2020

  1. Kuittinen, T, Rovio, P, Luukkaala, T, Laurila, M, Grénman, S, Kallioniemi, A et al.. Paclitaxel, Carboplatin and 1,25-D3 Inhibit Proliferation of Ovarian Cancer Cells . Anticancer Res. 2020;40 (6):3129-3138. doi: 10.21873/anticanres.14294. PubMed PMID:32487607 .

Search PubMed

2019

  1. Nurmi, A, Muranen, TA, Pelttari, LM, Kiiski, JI, Heikkinen, T, Lehto, S et al.. Recurrent moderate-risk mutations in Finnish breast and ovarian cancer patients. Int J Cancer. 2019;145 (10):2692-2700. doi: 10.1002/ijc.32309. PubMed PMID:30927251 PubMed Central PMC6767104.
  2. Vuorinen, EM, Rajala, NK, Ihalainen, TO, Kallioniemi, A. Correction to: Depletion of nuclear import protein karyopherin alpha 7 (KPNA7) induces mitotic defects and deformation of nuclei in cancer cells. BMC Cancer. 2019;19 (1):57. doi: 10.1186/s12885-018-5234-4. PubMed PMID:30642282 PubMed Central PMC6330744.

Search PubMed

2018

  1. Luhtala, S, Staff, S, Kallioniemi, A, Tanner, M, Isola, J. Clinicopathological and prognostic correlations of HER3 expression and its degradation regulators, NEDD4-1 and NRDP1, in primary breast cancer. BMC Cancer. 2018;18 (1):1045. doi: 10.1186/s12885-018-4917-1. PubMed PMID:30367623 PubMed Central PMC6204010.
  2. Abu Khamidakh, AE, Rodriguez-Martinez, A, Kaarniranta, K, Kallioniemi, A, Skottman, H, Hyttinen, J et al.. Wound healing of human embryonic stem cell-derived retinal pigment epithelial cells is affected by maturation stage. Biomed Eng Online. 2018;17 (1):102. doi: 10.1186/s12938-018-0535-z. PubMed PMID:30064430 PubMed Central PMC6069779.
  3. Vuorinen, EM, Rajala, NK, Ihalainen, TO, Kallioniemi, A. Depletion of nuclear import protein karyopherin alpha 7 (KPNA7) induces mitotic defects and deformation of nuclei in cancer cells. BMC Cancer. 2018;18 (1):325. doi: 10.1186/s12885-018-4261-5. PubMed PMID:29580221 PubMed Central PMC5870926.
  4. Ampuja, M, Kallioniemi, A. Transcription factors-Intricate players of the bone morphogenetic protein signaling pathway. Genes Chromosomes Cancer. 2018;57 (1):3-11. doi: 10.1002/gcc.22502. PubMed PMID:28857319 .

Search PubMed

Pirkko Kellokumpu-Lehtinen – Radiotherapy and Oncology
2020

  1. Kellokumpu-Lehtinen, PL, Marttila, T, Jekunen, A, Hervonen, P, Klintrup, K, Kataja, V et al.. Biweekly Cabazitaxel Is a Safe Treatment Option for Metastatic Castration-resistant Prostate Cancer (mCRPC) Patients After Docetaxel – A Final Analysis of the Prosty II Trial. Anticancer Res. 2020;40 (12):6915-6921. doi: 10.21873/anticanres.14715. PubMed PMID:33288585 .
  2. Takala, L, Kuusinen, TE, Skyttä, T, Kellokumpu-Lehtinen, PL, Bärlund, M. Electronic Patient-reported Outcomes During Breast Cancer Adjuvant Radiotherapy. Clin Breast Cancer. 2021;21 (3):e252-e270. doi: 10.1016/j.clbc.2020.10.004. PubMed PMID:33229222 .
  3. Kellokumpu-Lehtinen, PL, Hjälm-Eriksson, M, Thellenberg-Karlsson, C, Åström, L, Franzen, L, Fransson, AF et al.. Corrigendum re ”Docetaxel Versus Surveillance After Radical Radiotherapy for Intermediate- or High-risk Prostate Cancer-Results from the Prospective, Randomised, Open-label Phase III SPCG-13 Trial” [Eur Urol 2019;76:823-30]. Eur Urol. 2020;78 (6):e241-e242. doi: 10.1016/j.eururo.2020.08.035. PubMed PMID:32893063 .
  4. Vehmanen, L, Sievänen, H, Kellokumpu-Lehtinen, P, Nikander, R, Huovinen, R, Ruohola, J et al.. Five-year follow-up results of aerobic and impact training on bone mineral density in early breast cancer patients. Osteoporos Int. 2021;32 (3):473-482. doi: 10.1007/s00198-020-05611-w. PubMed PMID:32886189 PubMed Central PMC7929955.
  5. Pollari, M, Pellinen, T, Karjalainen-Lindsberg, ML, Kellokumpu-Lehtinen, PL, Leivonen, SK, Leppä, S et al.. Adverse prognostic impact of regulatory T-cells in testicular diffuse large B-cell lymphoma. Eur J Haematol. 2020;105 (6):712-721. doi: 10.1111/ejh.13484. PubMed PMID:32632935 .
  6. Lehtonen, M, Heiskanen, L, Reinikainen, P, Kellokumpu-Lehtinen, PL. Both comorbidity and worse performance status are associated with poorer overall survival after external beam radiotherapy for prostate cancer. BMC Cancer. 2020;20 (1):324. doi: 10.1186/s12885-020-06812-6. PubMed PMID:32295542 PubMed Central PMC7160996.
  7. Swain, SM, Miles, D, Kim, SB, Im, YH, Im, SA, Semiglazov, V et al.. Pertuzumab, trastuzumab, and docetaxel for HER2-positive metastatic breast cancer (CLEOPATRA): end-of-study results from a double-blind, randomised, placebo-controlled, phase 3 study. Lancet Oncol. 2020;21 (4):519-530. doi: 10.1016/S1470-2045(19)30863-0. PubMed PMID:32171426 .
  8. Roine, E, Sintonen, H, Kellokumpu-Lehtinen, PL, Penttinen, H, Utriainen, M, Vehmanen, L et al.. Health-related Quality of Life of Breast Cancer Survivors Attending an Exercise Intervention Study: A Five-year Follow-up. In Vivo. 2020;34 (2):667-674. doi: 10.21873/invivo.11821. PubMed PMID:32111767 PubMed Central PMC7157873.
  9. Sonnenblick, A, Salmon-Divon, M, Salgado, R, Dvash, E, Pondé, N, Zahavi, T et al.. Reactive stroma and trastuzumab resistance in HER2-positive early breast cancer. Int J Cancer. 2020;147 (1):266-276. doi: 10.1002/ijc.32859. PubMed PMID:31904863 .
  10. Aula, H, Skyttä, T, Tuohinen, S, Luukkaala, T, Hämäläinen, M, Virtanen, V et al.. ST2 levels increased and were associated with changes in left ventricular systolic function during a three-year follow-up after adjuvant radiotherapy for breast cancer. Breast. 2020;49 :183-186. doi: 10.1016/j.breast.2019.12.001. PubMed PMID:31862685 PubMed Central PMC7375584.

Search PubMed

2019

  1. Aula, H, Skyttä, T, Tuohinen, S, Luukkaala, T, Hämäläinen, M, Virtanen, V et al.. ST2 levels increased and were associated with changes in left ventricular systolic function during a three-year follow-up after adjuvant radiotherapy for breast cancer. Breast. 2020;49 :183-186. doi: 10.1016/j.breast.2019.12.001. PubMed PMID:31862685 PubMed Central PMC7375584.
  2. Lehtomaki, KI, Lahtinen, LI, Rintanen, N, Kuopio, T, Kholova, I, Makela, R et al.. Clonal Evolution of MEK/MAPK Pathway Activating Mutations in a Metastatic Colorectal Cancer Case. Anticancer Res. 2019;39 (11):5867-5877. doi: 10.21873/anticanres.13791. PubMed PMID:31704811 .
  3. Vuorinen, RL, Paunu, N, Turpeenniemi-Hujanen, T, Reunamo, T, Jekunen, A, Kataja, V et al.. Sunitinib First-line Treatment in Metastatic Renal Cell Carcinoma: Costs and Effects. Anticancer Res. 2019;39 (10):5559-5564. doi: 10.21873/anticanres.13749. PubMed PMID:31570450 .
  4. Kaikkonen, E, Ettala, O, Nikulainen, I, Taimen, P, Lehtinen, I, Boström, PJ et al.. rs77559646 Is Associated With First-line Docetaxel Treatment Response in Metastatic Castration-resistant Prostate Cancer. Anticancer Res. 2019;39 (10):5353-5359. doi: 10.21873/anticanres.13728. PubMed PMID:31570429 .
  5. Aula, H, Skyttä, T, Tuohinen, S, Luukkaala, T, Hämäläinen, M, Virtanen, V et al.. Transforming growth factor beta 1 levels predict echocardiographic changes at three years after adjuvant radiotherapy for breast cancer. Radiat Oncol. 2019;14 (1):155. doi: 10.1186/s13014-019-1366-1. PubMed PMID:31470867 PubMed Central PMC6717329.
  6. Kellokumpu-Lehtinen, PL, Hjälm-Eriksson, M, Thellenberg-Karlsson, C, Åström, L, Franzen, L, Fransson, AS et al.. Docetaxel Versus Surveillance After Radical Radiotherapy for Intermediate- or High-risk Prostate Cancer-Results from the Prospective, Randomised, Open-label Phase III SPCG-13 Trial. Eur Urol. 2019;76 (6):823-830. doi: 10.1016/j.eururo.2019.08.010. PubMed PMID:31443961 .
  7. Piili, RP, Lehto, JT, Metsänoja, R, Hinkka, H, Kellokumpu-Lehtinen, PI. Has there been a change in the end-of-life decision-making over the past 16 years?. BMJ Support Palliat Care. 2019; :. doi: 10.1136/bmjspcare-2019-001802. PubMed PMID:31395612 .
  8. Hackman, G, Taari, K, Tammela, TL, Matikainen, M, Kouri, M, Joensuu, T et al.. Randomised Trial of Adjuvant Radiotherapy Following Radical Prostatectomy Versus Radical Prostatectomy Alone in Prostate Cancer Patients with Positive Margins or Extracapsular Extension. Eur Urol. 2019;76 (5):586-595. doi: 10.1016/j.eururo.2019.07.001. PubMed PMID:31375279 .
  9. Tuohinen, SS, Skytta, T, Huhtala, H, Virtanen, V, Kellokumpu-Lehtinen, PL, Raatikainen, P et al.. Left Ventricular Speckle Tracking Echocardiography Changes Among Early-stage Breast Cancer Patients Three Years After Radiotherapy. Anticancer Res. 2019;39 (8):4227-4236. doi: 10.21873/anticanres.13584. PubMed PMID:31366510 .
  10. Terävä, J, Tiainen, L, Lamminmäki, U, Kellokumpu-Lehtinen, PL, Pettersson, K, Gidwani, K et al.. Lectin nanoparticle assays for detecting breast cancer-associated glycovariants of cancer antigen 15-3 (CA15-3) in human plasma. PLoS One. 2019;14 (7):e0219480. doi: 10.1371/journal.pone.0219480. PubMed PMID:31344060 PubMed Central PMC6658058.
  11. Tiainen, L, Korhonen, EA, Leppänen, VM, Luukkaala, T, Hämäläinen, M, Tanner, M et al.. High baseline Tie1 level predicts poor survival in metastatic breast cancer. BMC Cancer. 2019;19 (1):732. doi: 10.1186/s12885-019-5959-8. PubMed PMID:31340773 PubMed Central PMC6657075.
  12. Auvray, M, Auclin, E, Barthelemy, P, Bono, P, Kellokumpu-Lehtinen, P, Gross-Goupil, M et al.. Erratum to ’Second-line targeted therapies after nivolumab-ipilimumab failure in metastatic renal cell carcinoma’ [Eur J Cancer 108 (February 2019) 33-40]. Eur J Cancer. 2019;119 :200-201. doi: 10.1016/j.ejca.2019.04.012. PubMed PMID:31301937 .
  13. Wu, X, Reinikainen, P, Kapanen, M, Vierikko, T, Ryymin, P, Kellokumpu-Lehtinen, PL et al.. Monitoring radiotherapy induced tissue changes in localized prostate cancer by multi-parametric magnetic resonance imaging (MP-MRI). Diagn Interv Imaging. 2019;100 (11):699-708. doi: 10.1016/j.diii.2019.06.003. PubMed PMID:31257114 .
  14. Skyttä, T, Tuohinen, S, Luukkaala, T, Virtanen, V, Raatikainen, P, Kellokumpu-Lehtinen, PL et al.. Adjuvant radiotherapy-induced cardiac changes among patients with early breast cancer: a three-year follow-up study. Acta Oncol. 2019;58 (9):1250-1258. doi: 10.1080/0284186X.2019.1630751. PubMed PMID:31219359 .
  15. Mannisto, S, Vähämurto, P, Pollari, M, Clausen, MR, Jyrkkiö, S, Kellokumpu-Lehtinen, PL et al.. Intravenous but not intrathecal central nervous system-directed chemotherapy improves survival in patients with testicular diffuse large B-cell lymphoma. Eur J Cancer. 2019;115 :27-36. doi: 10.1016/j.ejca.2019.04.004. PubMed PMID:31082690 .
  16. Tiainen, L, Hämäläinen, M, Luukkaala, T, Tanner, M, Lahdenperä, O, Vihinen, P et al.. Low Plasma IL-8 Levels During Chemotherapy Are Predictive of Excellent Long-Term Survival in Metastatic Breast Cancer. Clin Breast Cancer. 2019;19 (4):e522-e533. doi: 10.1016/j.clbc.2019.03.006. PubMed PMID:31029558 .
  17. Alminoja, A, Piili, RP, Hinkka, H, Metsänoja, R, Hirvonen, O, Tyynelä-Korhonen, K et al.. Does Decision-making in End-of-life Care Differ Between Graduating Medical Students and Experienced Physicians?. In Vivo. 2019;33 (3):903-909. doi: 10.21873/invivo.11557. PubMed PMID:31028215 PubMed Central PMC6559926.
  18. Penttinen, H, Utriainen, M, Kellokumpu-Lehtinen, PL, Raitanen, J, Sievänen, H, Nikander, R et al.. Effectiveness of a 12-month Exercise Intervention on Physical Activity and Quality of Life of Breast Cancer Survivors; Five-year Results of the BREX-study. In Vivo. 2019;33 (3):881-888. doi: 10.21873/invivo.11554. PubMed PMID:31028212 PubMed Central PMC6559915.
  19. Loi, S, Drubay, D, Adams, S, Pruneri, G, Francis, PA, Lacroix-Triki, M et al.. Tumor-Infiltrating Lymphocytes and Prognosis: A Pooled Individual Patient Analysis of Early-Stage Triple-Negative Breast Cancers. J Clin Oncol. 2019;37 (7):559-569. doi: 10.1200/JCO.18.01010. PubMed PMID:30650045 PubMed Central PMC7010425.
  20. Auvray, M, Auclin, E, Barthelemy, P, Bono, P, Kellokumpu-Lehtinen, P, Gross-Goupil, M et al.. Second-line targeted therapies after nivolumab-ipilimumab failure in metastatic renal cell carcinoma. Eur J Cancer. 2019;108 :33-40. doi: 10.1016/j.ejca.2018.11.031. PubMed PMID:30616146 .
  21. Takala, L, Bärlund, M, Kellokumpu-Lehtinen, PL. Effective Antiemetic Therapy Is Important With Adjuvant Anthracycline-based Chemotherapy in Breast Cancer. Anticancer Res. 2019;39 (1):279-283. doi: 10.21873/anticanres.13108. PubMed PMID:30591469 .
  22. Lehto, US, Ojanen, M, Väkevä, A, Dyba, T, Aromaa, A, Kellokumpu-Lehtinen, P et al.. Early quality-of-life and psychological predictors of disease-free time and survival in localized prostate cancer. Qual Life Res. 2019;28 (3):677-686. doi: 10.1007/s11136-018-2069-z. PubMed PMID:30511254 PubMed Central PMC6394517.
  23. Leivonen, SK, Pollari, M, Brück, O, Pellinen, T, Autio, M, Karjalainen-Lindsberg, ML et al.. T-cell inflamed tumor microenvironment predicts favorable prognosis in primary testicular lymphoma. Haematologica. 2019;104 (2):338-346. doi: 10.3324/haematol.2018.200105. PubMed PMID:30237271 PubMed Central PMC6355505.

Search PubMed

2018

  1. Lehto, US, Ojanen, M, Väkevä, A, Dyba, T, Aromaa, A, Kellokumpu-Lehtinen, P et al.. Early quality-of-life and psychological predictors of disease-free time and survival in localized prostate cancer. Qual Life Res. 2019;28 (3):677-686. doi: 10.1007/s11136-018-2069-z. PubMed PMID:30511254 PubMed Central PMC6394517.
  2. Aula, H, Skyttä, T, Tuohinen, S, Luukkaala, T, Hämäläinen, M, Virtanen, V et al.. Decreases in TGF-β1 and PDGF levels are associated with echocardiographic changes during adjuvant radiotherapy for breast cancer. Radiat Oncol. 2018;13 (1):201. doi: 10.1186/s13014-018-1150-7. PubMed PMID:30340644 PubMed Central PMC6194684.
  3. Wu, X, Reinikainen, P, Kapanen, M, Vierikko, T, Ryymin, P, Kellokumpu-Lehtinen, PL et al.. Dynamic Contrast-Enhanced Imaging as a Prognostic Tool in Early Diagnosis of Prostate Cancer: Correlation with PSA and Clinical Stage. Contrast Media Mol Imaging. 2018;2018 :3181258. doi: 10.1155/2018/3181258. PubMed PMID:30327584 PubMed Central PMC6169212.
  4. Leivonen, SK, Pollari, M, Brück, O, Pellinen, T, Autio, M, Karjalainen-Lindsberg, ML et al.. T-cell inflamed tumor microenvironment predicts favorable prognosis in primary testicular lymphoma. Haematologica. 2019;104 (2):338-346. doi: 10.3324/haematol.2018.200105. PubMed PMID:30237271 PubMed Central PMC6355505.
  5. Kaikkonen, E, Rantapero, T, Zhang, Q, Taimen, P, Laitinen, V, Kallajoki, M et al.. ANO7 is associated with aggressive prostate cancer. Int J Cancer. 2018;143 (10):2479-2487. doi: 10.1002/ijc.31746. PubMed PMID:30157291 PubMed Central PMC6589920.
  6. Pollari, M, Brück, O, Pellinen, T, Vähämurto, P, Karjalainen-Lindsberg, ML, Mannisto, S et al.. PD-L1 tumor-associated macrophages and PD-1 tumor-infiltrating lymphocytes predict survival in primary testicular lymphoma. Haematologica. 2018;103 (11):1908-1914. doi: 10.3324/haematol.2018.197194. PubMed PMID:30026337 PubMed Central PMC6278972.
  7. Piili, RP, Lehto, JT, Luukkaala, T, Hinkka, H, Kellokumpu-Lehtinen, PI. Does special education in palliative medicine make a difference in end-of-life decision-making?. BMC Palliat Care. 2018;17 (1):94. doi: 10.1186/s12904-018-0349-6. PubMed PMID:30021586 PubMed Central PMC6052558.
  8. Joensuu, H, Fraser, J, Wildiers, H, Huovinen, R, Auvinen, P, Utriainen, M et al.. Effect of Adjuvant Trastuzumab for a Duration of 9 Weeks vs 1 Year With Concomitant Chemotherapy for Early Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer: The SOLD Randomized Clinical Trial. JAMA Oncol. 2018;4 (9):1199-1206. doi: 10.1001/jamaoncol.2018.1380. PubMed PMID:29852043 PubMed Central PMC6143012.
  9. Piili, RP, Metsänoja, R, Hinkka, H, Kellokumpu-Lehtinen, PI, Lehto, JT. Changes in attitudes towards hastened death among Finnish physicians over the past sixteen years. BMC Med Ethics. 2018;19 (1):40. doi: 10.1186/s12910-018-0290-5. PubMed PMID:29843682 PubMed Central PMC5975714.
  10. Tuohinen, SS, Keski-Pukkila, K, Skyttä, T, Huhtala, H, Virtanen, V, Kellokumpu-Lehtinen, PL et al.. Radiotherapy-induced Early ECG Changes and Their Comparison with Echocardiography in Patients with Early-stage Breast Cancer. Anticancer Res. 2018;38 (4):2207-2215. doi: 10.21873/anticanres.12463. PubMed PMID:29599341 .
  11. Motzer, RJ, Tannir, NM, McDermott, DF, Arén Frontera, O, Melichar, B, Choueiri, TK et al.. Nivolumab plus Ipilimumab versus Sunitinib in Advanced Renal-Cell Carcinoma. N Engl J Med. 2018;378 (14):1277-1290. doi: 10.1056/NEJMoa1712126. PubMed PMID:29562145 PubMed Central PMC5972549.
  12. Sperinde, J, Huang, W, Vehtari, A, Chenna, A, Kellokumpu-Lehtinen, PL, Winslow, J et al.. p95HER2 Methionine 611 Carboxy-Terminal Fragment Is Predictive of Trastuzumab Adjuvant Treatment Benefit in the FinHer Trial. Clin Cancer Res. 2018;24 (13):3046-3052. doi: 10.1158/1078-0432.CCR-17-3250. PubMed PMID:29535130 .
  13. Schmidt, M, Weyer-Elberich, V, Hengstler, JG, Heimes, AS, Almstedt, K, Gerhold-Ay, A et al.. Prognostic impact of CD4-positive T cell subsets in early breast cancer: a study based on the FinHer trial patient population. Breast Cancer Res. 2018;20 (1):15. doi: 10.1186/s13058-018-0942-x. PubMed PMID:29482642 PubMed Central PMC5827982.
  14. Ahlgren, GM, Flodgren, P, Tammela, TLJ, Kellokumpu-Lehtinen, P, Borre, M, Angelsen, A et al.. Docetaxel Versus Surveillance After Radical Prostatectomy for High-risk Prostate Cancer: Results from the Prospective Randomised, Open-label Phase 3 Scandinavian Prostate Cancer Group 12 Trial. Eur Urol. 2018;73 (6):870-876. doi: 10.1016/j.eururo.2018.01.012. PubMed PMID:29395502 .
  15. Hietanen, T, Kapanen, M, Kellokumpu-Lehtinen, PL. Natural Killer Cell Viability After Hyperthermia Alone or Combined with Radiotherapy with or without Cytokines. Anticancer Res. 2018;38 (2):655-663. doi: 10.21873/anticanres.12269. PubMed PMID:29374687 .
  16. Tuohinen, SS, Rankinen, J, Skyttä, T, Huhtala, H, Virtanen, V, Kellokumpu-Lehtinen, PL et al.. Associations between ECG changes and echocardiographic findings in patients with acute non-ST elevation myocardial infarction. J Electrocardiol. 2018;51 (2):188-194. doi: 10.1016/j.jelectrocard.2017.11.007. PubMed PMID:29174705 .
  17. Pajamäki, N, Metso, S, Hakala, T, Ebeling, T, Huhtala, H, Ryödi, E et al.. Long-term cardiovascular morbidity and mortality in patients treated for differentiated thyroid cancer. Clin Endocrinol (Oxf). 2018;88 (2):303-310. doi: 10.1111/cen.13519. PubMed PMID:29154445 .
  18. Gillessen, S, Attard, G, Beer, TM, Beltran, H, Bossi, A, Bristow, R et al.. Management of Patients with Advanced Prostate Cancer: The Report of the Advanced Prostate Cancer Consensus Conference APCCC 2017. Eur Urol. 2018;73 (2):178-211. doi: 10.1016/j.eururo.2017.06.002. PubMed PMID:28655541 .

Search PubMed

Olli Lohi – Hematology and oncology
2020

  1. Abuhamed, J, Nikkilä, A, Lohi, O, Auvinen, A. Trends of computed tomography use among children in Finland. Eur J Radiol Open. 2020;7 :100290. doi: 10.1016/j.ejro.2020.100290. PubMed PMID:33335951 PubMed Central PMC7733003.
  2. Mehtonen, J, Teppo, S, Lahnalampi, M, Kokko, A, Kaukonen, R, Oksa, L et al.. Single cell characterization of B-lymphoid differentiation and leukemic cell states during chemotherapy in ETV6-RUNX1-positive pediatric leukemia identifies drug-targetable transcription factor activities. Genome Med. 2020;12 (1):99. doi: 10.1186/s13073-020-00799-2. PubMed PMID:33218352 PubMed Central PMC7679990.
  3. Dufva, O, Pölönen, P, Brück, O, Keränen, MAI, Klievink, J, Mehtonen, J et al.. Immunogenomic Landscape of Hematological Malignancies. Cancer Cell. 2020;38 (3):424-428. doi: 10.1016/j.ccell.2020.08.019. PubMed PMID:32931743 .
  4. Laukkanen, S, Oksa, L, Nikkilä, A, Lahnalampi, M, Parikka, M, Seki, M et al.. SIX6 is a TAL1-regulated transcription factor in T-ALL and associated with inferior outcome. Leuk Lymphoma. 2020;61 (13):3089-3100. doi: 10.1080/10428194.2020.1804560. PubMed PMID:32835548 .
  5. Immonen, E, Aine, L, Nikkilä, A, Parikka, M, Grönroos, M, Vepsäläinen, K et al.. Randomized controlled and double-blinded study of Caphosol versus saline oral rinses in pediatric patients with cancer. Pediatr Blood Cancer. 2020;67 (10):e28520. doi: 10.1002/pbc.28520. PubMed PMID:32725875 .
  6. Chan, LN, Murakami, MA, Robinson, ME, Caeser, R, Sadras, T, Lee, J et al.. Signalling input from divergent pathways subverts B cell transformation. Nature. 2020;583 (7818):845-851. doi: 10.1038/s41586-020-2513-4. PubMed PMID:32699415 PubMed Central PMC7394729.
  7. Dufva, O, Pölönen, P, Brück, O, Keränen, MAI, Klievink, J, Mehtonen, J et al.. Immunogenomic Landscape of Hematological Malignancies. Cancer Cell. 2020;38 (3):380-399.e13. doi: 10.1016/j.ccell.2020.06.002. PubMed PMID:32649887 .
  8. Karalexi, MA, Dessypris, N, Ma, X, Spector, LG, Marcotte, E, Clavel, J et al.. Age-, sex- and disease subtype-related foetal growth differentials in childhood acute myeloid leukaemia risk: A Childhood Leukemia International Consortium analysis. Eur J Cancer. 2020;130 :1-11. doi: 10.1016/j.ejca.2020.01.018. PubMed PMID:32163883 .
  9. Nikkilä, A, Raitanen, J, Lohi, O, Auvinen, A. Radiation exposure from computerized tomography and risk of childhood leukemia: Finnish register-based case-control study of childhood leukemia (FRECCLE). Haematologica. 2020;105 (3):849-850. doi: 10.3324/haematol.2019.245704. PubMed PMID:32115415 PubMed Central PMC7049358.
  10. Grönroos, T, Mäkinen, A, Laukkanen, S, Mehtonen, J, Nikkilä, A, Oksa, L et al.. Clinicopathological features and prognostic value of SOX11 in childhood acute lymphoblastic leukemia. Sci Rep. 2020;10 (1):2043. doi: 10.1038/s41598-020-58970-z. PubMed PMID:32029838 PubMed Central PMC7005266.
  11. Nikkilä, A, Arvela, H, Mehtonen, J, Raitanen, J, Heinäniemi, M, Lohi, O et al.. Predicting residential radon concentrations in Finland: Model development, validation, and application to childhood leukemia. Scand J Work Environ Health. 2020;46 (3):278-292. doi: 10.5271/sjweh.3867. PubMed PMID:31763683 .
  12. Harjula, SE, Saralahti, AK, Ojanen, MJT, Rantapero, T, Uusi-Mäkelä, MIE, Nykter, M et al.. Characterization of immune response against Mycobacterium marinum infection in the main hematopoietic organ of adult zebrafish (Danio rerio). Dev Comp Immunol. 2020;103 :103523. doi: 10.1016/j.dci.2019.103523. PubMed PMID:31626817 .
  13. Heikkilä, P, Kokko, P, Lohi, O, Korppi, M. Nursing intensity scores did not correlate well with reimbursement claims for infant bronchiolitis. Acta Paediatr. 2020;109 (1):140-146. doi: 10.1111/apa.14926. PubMed PMID:31269265 .

Search PubMed

2019

  1. Karppinen, S, Lohi, O, Vihola, M. Prediction of leukocyte counts during paediatric acute lymphoblastic leukaemia maintenance therapy. Sci Rep. 2019;9 (1):18076. doi: 10.1038/s41598-019-54492-5. PubMed PMID:31792398 PubMed Central PMC6889389.
  2. Nikkilä, A, Arvela, H, Mehtonen, J, Raitanen, J, Heinäniemi, M, Lohi, O et al.. Predicting residential radon concentrations in Finland: Model development, validation, and application to childhood leukemia. Scand J Work Environ Health. 2020;46 (3):278-292. doi: 10.5271/sjweh.3867. PubMed PMID:31763683 .
  3. Harjula, SE, Saralahti, AK, Ojanen, MJT, Rantapero, T, Uusi-Mäkelä, MIE, Nykter, M et al.. Characterization of immune response against Mycobacterium marinum infection in the main hematopoietic organ of adult zebrafish (Danio rerio). Dev Comp Immunol. 2020;103 :103523. doi: 10.1016/j.dci.2019.103523. PubMed PMID:31626817 .
  4. Talibov, M, Olsson, A, Bailey, H, Erdmann, F, Metayer, C, Magnani, C et al.. Parental occupational exposure to low-frequency magnetic fields and risk of leukaemia in the offspring: findings from the Childhood Leukaemia International Consortium (CLIC). Occup Environ Med. 2019;76 (10):746-753. doi: 10.1136/oemed-2019-105706. PubMed PMID:31358566 PubMed Central PMC6817988.
  5. Mehtonen, J, Pölönen, P, Häyrynen, S, Dufva, O, Lin, J, Liuksiala, T et al.. Data-driven characterization of molecular phenotypes across heterogeneous sample collections. Nucleic Acids Res. 2019;47 (13):e76. doi: 10.1093/nar/gkz281. PubMed PMID:31329928 PubMed Central PMC6648337.
  6. Heikkilä, P, Kokko, P, Lohi, O, Korppi, M. Nursing intensity scores did not correlate well with reimbursement claims for infant bronchiolitis. Acta Paediatr. 2020;109 (1):140-146. doi: 10.1111/apa.14926. PubMed PMID:31269265 .
  7. Pölönen, P, Mehtonen, J, Lin, J, Liuksiala, T, Häyrynen, S, Teppo, S et al.. Hemap: An Interactive Online Resource for Characterizing Molecular Phenotypes across Hematologic Malignancies. Cancer Res. 2019;79 (10):2466-2479. doi: 10.1158/0008-5472.CAN-18-2970. PubMed PMID:30940663 .
  8. Wolthers, BO, Mogensen, PR, Frandsen, TL, Abrahamsson, J, Behrendtz, M, Heyman, M et al.. Insulin-dependent diabetes: A chronic complication to acute pancreatitis in childhood acute lymphoblastic leukemia. Pediatr Blood Cancer. 2019;66 (1):e27437. doi: 10.1002/pbc.27437. PubMed PMID:30216644 .
  9. Poukka, M, Lund-Aho, T, Raittinen, P, Nikkilä, A, Kivinen, K, Lundán, T et al.. Acute Lymphoblastic Leukemia With INPP5D-ABL1 Fusion Responds to Imatinib Treatment. J Pediatr Hematol Oncol. 2019;41 (7):e481-e483. doi: 10.1097/MPH.0000000000001267. PubMed PMID:30045148 .

Search PubMed

2018

  1. Wolthers, BO, Mogensen, PR, Frandsen, TL, Abrahamsson, J, Behrendtz, M, Heyman, M et al.. Insulin-dependent diabetes: A chronic complication to acute pancreatitis in childhood acute lymphoblastic leukemia. Pediatr Blood Cancer. 2019;66 (1):e27437. doi: 10.1002/pbc.27437. PubMed PMID:30216644 .
  2. Nikkilä, A, Raitanen, J, Lohi, O, Auvinen, A. Radiation exposure from computerized tomography and risk of childhood leukemia: Finnish register-based case-control study of childhood leukemia (FRECCLE). Haematologica. 2018;103 (11):1873-1880. doi: 10.3324/haematol.2018.187716. PubMed PMID:29976736 PubMed Central PMC6278981.
  3. Nikkilä, A, Kendall, G, Raitanen, J, Spycher, B, Lohi, O, Auvinen, A et al.. Effects of incomplete residential histories on studies of environmental exposure with application to childhood leukaemia and background radiation. Environ Res. 2018;166 :466-472. doi: 10.1016/j.envres.2018.06.035. PubMed PMID:29945121 .
  4. Nordfors, K, Haapasalo, J, Afyounian, E, Tuominen, J, Annala, M, Häyrynen, S et al.. Erratum: Whole-exome sequencing identifies germline mutation in and in a child with genomically aberrant AT/RT and her mother with anaplastic astrocytoma. Cold Spring Harb Mol Case Stud. 2018;4 (3):. doi: 10.1101/mcs.a003129. PubMed PMID:29858379 PubMed Central PMC5983177.
  5. Nordfors, K, Haapasalo, J, Afyounian, E, Tuominen, J, Annala, M, Häyrynen, S et al.. Whole-exome sequencing identifies germline mutation in and in a child with genomically aberrant AT/RT and her mother with anaplastic astrocytoma. Cold Spring Harb Mol Case Stud. 2018;4 (2):. doi: 10.1101/mcs.a002246. PubMed PMID:29602769 PubMed Central PMC5880256.
  6. de Bock, CE, Demeyer, S, Degryse, S, Verbeke, D, Sweron, B, Gielen, O et al.. HOXA9 Cooperates with Activated JAK/STAT Signaling to Drive Leukemia Development. Cancer Discov. 2018;8 (5):616-631. doi: 10.1158/2159-8290.CD-17-0583. PubMed PMID:29496663 .
  7. Norberg, A, Rosén, A, Raaschou-Jensen, K, Kjeldsen, L, Moilanen, JS, Paulsson-Karlsson, Y et al.. Novel variants in Nordic patients referred for genetic testing of telomere-related disorders. Eur J Hum Genet. 2018;26 (6):858-867. doi: 10.1038/s41431-018-0112-8. PubMed PMID:29483670 PubMed Central PMC5974393.

Search PubMed

Johanna Mäenpää – Gynaecological oncology
2020

  1. Jäntti, T, Luhtala, S, Mäenpää, J, Staff, S. Characterization of immunoreactivity with whole-slide imaging and digital analysis in high-grade serous ovarian cancer. Tumour Biol. 2020;42 (11):1010428320971404. doi: 10.1177/1010428320971404. PubMed PMID:33169632 .
  2. Veijalainen, O, Kares, S, Kotaniemi-Talonen, L, Kujala, P, Vuento, R, Luukkaala, T et al.. Primary HPV screening for cervical cancer: Results after two screening rounds in a regional screening program in Finland. Acta Obstet Gynecol Scand. 2021;100 (3):403-409. doi: 10.1111/aogs.14021. PubMed PMID:33037625 .
  3. Savolainen, K, Scaravilli, M, Ilvesmäki, A, Staff, S, Tolonen, T, Mäenpää, JU et al.. Expression of the miR-200 family in tumor tissue, plasma and urine of epithelial ovarian cancer patients in comparison to benign counterparts. BMC Res Notes. 2020;13 (1):311. doi: 10.1186/s13104-020-05155-6. PubMed PMID:32611374 PubMed Central PMC7329467.
  4. Kuittinen, T, Rovio, P, Luukkaala, T, Laurila, M, Grénman, S, Kallioniemi, A et al.. Paclitaxel, Carboplatin and 1,25-D3 Inhibit Proliferation of Ovarian Cancer Cells . Anticancer Res. 2020;40 (6):3129-3138. doi: 10.21873/anticanres.14294. PubMed PMID:32487607 .
  5. Huttala, O, Staff, S, Heinonen, T, Mäenpää, J, Tanner, M, Ylikomi, T et al.. In Vitro Vascular Network Modified to Function as Culture Platform and Angiogenic Induction Potential Test for Cancer Cells. Int J Mol Sci. 2020;21 (5):. doi: 10.3390/ijms21051833. PubMed PMID:32155897 PubMed Central PMC7084873.
  6. Rohr, I, Alavi, S, Richter, R, Keller, M, Chekerov, R, Oskay-Özcelik, G et al.. Expectations and preferences of patients with primary and relapsed ovarian cancer to maintenance therapy: A NOGGO/ENGOT-ov22 and GCIG survey (Expression IV). Int J Gynecol Cancer. 2020;30 (4):509-514. doi: 10.1136/ijgc-2019-000892. PubMed PMID:32139438 .
  7. Aalto, A, Huotari-Orava, R, Luhtala, S, Mäenpää, J, Staff, S. Expression of Estrogen-Related Receptors in Localized Provoked Vulvodynia. Biores Open Access. 2020;9 (1):13-21. doi: 10.1089/biores.2019.0049. PubMed PMID:32117596 PubMed Central PMC7047250.
  8. Kalamo, MH, Mäenpää, JU, Seppälä, TT, Mecklin, JP, Huhtala, H, Sorvettula, K et al.. Factors associated with decision-making on prophylactic hysterectomy and attitudes towards gynecological surveillance among women with Lynch syndrome (LS): a descriptive study. Fam Cancer. 2020;19 (2):177-182. doi: 10.1007/s10689-020-00158-5. PubMed PMID:31997047 PubMed Central PMC7101284.
  9. Vuorinen, RK, Luukkaala, TH, Mäenpää, JU. The influence of bevacizumab on the costs of ovarian cancer treatment in routine clinical practice. Acta Oncol. 2020;59 (4):453-457. doi: 10.1080/0284186X.2019.1711175. PubMed PMID:31920123 .
  10. Antila, RM, Mäenpää, JU, Huhtala, HS, Tomás, EI, Staff, SM. Association of cesarean scar defect with abnormal uterine bleeding: The results of a prospective study. Eur J Obstet Gynecol Reprod Biol. 2020;244 :134-140. doi: 10.1016/j.ejogrb.2019.11.021. PubMed PMID:31785470 .

Search PubMed

2019

  1. Ray-Coquard, I, Pautier, P, Pignata, S, Pérol, D, González-Martín, A, Berger, R et al.. Olaparib plus Bevacizumab as First-Line Maintenance in Ovarian Cancer. N Engl J Med. 2019;381 (25):2416-2428. doi: 10.1056/NEJMoa1911361. PubMed PMID:31851799 .
  2. Antila, RM, Mäenpää, JU, Huhtala, HS, Tomás, EI, Staff, SM. Association of cesarean scar defect with abnormal uterine bleeding: The results of a prospective study. Eur J Obstet Gynecol Reprod Biol. 2020;244 :134-140. doi: 10.1016/j.ejogrb.2019.11.021. PubMed PMID:31785470 .
  3. González-Martín, A, Pothuri, B, Vergote, I, DePont Christensen, R, Graybill, W, Mirza, MR et al.. Niraparib in Patients with Newly Diagnosed Advanced Ovarian Cancer. N Engl J Med. 2019;381 (25):2391-2402. doi: 10.1056/NEJMoa1910962. PubMed PMID:31562799 .
  4. Mirza, MR, Åvall Lundqvist, E, Birrer, MJ, dePont Christensen, R, Nyvang, GB, Malander, S et al.. Niraparib plus bevacizumab versus niraparib alone for platinum-sensitive recurrent ovarian cancer (NSGO-AVANOVA2/ENGOT-ov24): a randomised, phase 2, superiority trial. Lancet Oncol. 2019;20 (10):1409-1419. doi: 10.1016/S1470-2045(19)30515-7. PubMed PMID:31474354 .
  5. Kares, S, Veijalainen, O, Kholová, I, Tirkkonen, M, Vuento, R, Huhtala, H et al.. HIGH-RISK HPV testing as the primary screening method in an organized regional screening program for cervical cancer: the value of HPV16 and HPV18 genotyping?. APMIS. 2019;127 (11):710-716. doi: 10.1111/apm.12990. PubMed PMID:31403733 .
  6. Mirza, MR, Bergmann, TK, Mau-Sørensen, M, Christensen, RD, Åvall-Lundqvist, E, Birrer, MJ et al.. A phase I study of the PARP inhibitor niraparib in combination with bevacizumab in platinum-sensitive epithelial ovarian cancer: NSGO AVANOVA1/ENGOT-OV24. Cancer Chemother Pharmacol. 2019;84 (4):791-798. doi: 10.1007/s00280-019-03917-z. PubMed PMID:31375879 .
  7. Falconer, H, Palsdottir, K, Stalberg, K, Dahm-Kähler, P, Ottander, U, Lundin, ES et al.. Robot-assisted approach to cervical cancer (RACC): an international multi-center, open-label randomized controlled trial. Int J Gynecol Cancer. 2019;29 (6):1072-1076. doi: 10.1136/ijgc-2019-000558. PubMed PMID:31203203 .
  8. Aalto, AP, Huhtala, H, Mäenpää, J, Staff, S. Combination of Treatments With or Without Surgery in Localized Provoked Vulvodynia: Outcomes After Three Years of Follow-Up. Biores Open Access. 2019;8 (1):25-31. doi: 10.1089/biores.2018.0044. PubMed PMID:30867980 PubMed Central PMC6415354.
  9. Bhatla, N, Berek, JS, Cuello Fredes, M, Denny, LA, Grenman, S, Karunaratne, K et al.. Revised FIGO staging for carcinoma of the cervix uteri. Int J Gynaecol Obstet. 2019;145 (1):129-135. doi: 10.1002/ijgo.12749. PubMed PMID:30656645 .
  10. Lagerstedt, M, Huotari-Orava, R, Nyberg, R, Nissinen, L, Farshchian, M, Laasanen, SL et al.. Tumor cell-specific Serpin A1 expression in vulvar squamous cell carcinoma. Arch Gynecol Obstet. 2019;299 (5):1345-1351. doi: 10.1007/s00404-018-5015-y. PubMed PMID:30607583 PubMed Central PMC6475512.
  11. Veijalainen, O, Kares, S, Kujala, P, Vuento, R, Osuala, V, Tirkkonen, M et al.. Implementation of HPV-based cervical cancer screening in an organised regional screening programme: 3 years of experience. Cytopathology. 2019;30 (2):150-156. doi: 10.1111/cyt.12652. PubMed PMID:30421573 .

Search PubMed

2018

  1. Veijalainen, O, Kares, S, Kujala, P, Vuento, R, Osuala, V, Tirkkonen, M et al.. Implementation of HPV-based cervical cancer screening in an organised regional screening programme: 3 years of experience. Cytopathology. 2019;30 (2):150-156. doi: 10.1111/cyt.12652. PubMed PMID:30421573 .
  2. Niemi, RJ, Braicu, EI, Kulbe, H, Koistinen, KM, Sehouli, J, Puistola, U et al.. Ovarian tumours of different histologic type and clinical stage induce similar changes in lipid metabolism. Br J Cancer. 2018;119 (7):847-854. doi: 10.1038/s41416-018-0270-z. PubMed PMID:30293997 PubMed Central PMC6189177.
  3. Niemi, RJ, Roine, AN, Eräviita, E, Kumpulainen, PS, Mäenpää, JU, Oksala, N et al.. FAIMS analysis of urine gaseous headspace is capable of differentiating ovarian cancer. Gynecol Oncol. 2018;151 (3):519-524. doi: 10.1016/j.ygyno.2018.09.016. PubMed PMID:30257785 .
  4. Antila-Långsjö, RM, Mäenpää, JU, Huhtala, HS, Tomás, EI, Staff, SM. Cesarean scar defect: a prospective study on risk factors. Am J Obstet Gynecol. 2018;219 (5):458.e1-458.e8. doi: 10.1016/j.ajog.2018.09.004. PubMed PMID:30240650 .
  5. Veskimäe, K, Scaravilli, M, Niininen, W, Karvonen, H, Jaatinen, S, Nykter, M et al.. Expression Analysis of Platinum Sensitive and Resistant Epithelial Ovarian Cancer Patient Samples Reveals New Candidates for Targeted Therapies. Transl Oncol. 2018;11 (5):1160-1170. doi: 10.1016/j.tranon.2018.07.010. PubMed PMID:30056367 PubMed Central PMC6079561.
  6. Antila-Långsjö, R, Mäenpää, JU, Huhtala, H, Tomás, E, Staff, S. Comparison of transvaginal ultrasound and saline contrast sonohysterography in evaluation of cesarean scar defect: a prospective cohort study. Acta Obstet Gynecol Scand. 2018;97 (9):1130-1136. doi: 10.1111/aogs.13367. PubMed PMID:29754409 .
  7. Mäenpää, MM, Nieminen, K, Tomás, EI, Luukkaala, TH, Mäenpää, JU. Robotic-Assisted Infrarenal Para-aortic Lymphadenectomy in Gynecological Cancers: Technique and Surgical Outcomes. Int J Gynecol Cancer. 2018;28 (5):951-958. doi: 10.1097/IGC.0000000000001249. PubMed PMID:29683877 .
  8. Palmér, R, Mäenpää, J, Jauhiainen, A, Larsson, B, Mo, J, Russell, M et al.. Dipeptidyl Peptidase 1 Inhibitor AZD7986 Induces a Sustained, Exposure-Dependent Reduction in Neutrophil Elastase Activity in Healthy Subjects. Clin Pharmacol Ther. 2018;104 (6):1155-1164. doi: 10.1002/cpt.1053. PubMed PMID:29484635 PubMed Central PMC6282495.

Search PubMed

Daniela Ungureanu – Cancer Signalling
2020

  1. Ungureanu, DR, Zorila, LG, Capitanescu, RG, Iliescu, DG. First trimester cerebral appearance in the presence of closed spina bifida with myelomeningocele, part of the oeis complex. BMJ Case Rep. 2020;13 (10):. doi: 10.1136/bcr-2020-235395. PubMed PMID:33033002 PubMed Central PMC7545505.
  2. Karvonen, H, Arjama, M, Kaleva, L, Niininen, W, Barker, H, Koivisto-Korander, R et al.. Glucocorticoids induce differentiation and chemoresistance in ovarian cancer by promoting ROR1-mediated stemness. Cell Death Dis. 2020;11 (9):790. doi: 10.1038/s41419-020-03009-4. PubMed PMID:32989221 PubMed Central PMC7522257.
  3. Sheetz, JB, Mathea, S, Karvonen, H, Malhotra, K, Chatterjee, D, Niininen, W et al.. Structural Insights into Pseudokinase Domains of Receptor Tyrosine Kinases. Mol Cell. 2020;79 (3):390-405.e7. doi: 10.1016/j.molcel.2020.06.018. PubMed PMID:32619402 PubMed Central PMC7543951.

Search PubMed

2019

  1. Karvonen, H, Barker, H, Kaleva, L, Niininen, W, Ungureanu, D. Molecular Mechanisms Associated with ROR1-Mediated Drug Resistance: Crosstalk with Hippo-YAP/TAZ and BMI-1 Pathways. Cells. 2019;8 (8):. doi: 10.3390/cells8080812. PubMed PMID:31382410 PubMed Central PMC6721603.
  2. Tudor, Ș, Minciună, C, Lăcătuş, M, Gavrilă, D, Manciu, S, Ungureanu, D et al.. Transanal Total Mesorectal Excision – A Case Report. Chirurgia (Bucur). 2019;114 (2):278-283. doi: 10.21614/chirurgia.114.2.278. PubMed PMID:31060661 .
  3. Karvonen, H, Perttilä, R, Niininen, W, Hautanen, V, Barker, H, Murumägi, A et al.. Wnt5a and ROR1 activate non-canonical Wnt signaling via RhoA in TCF3-PBX1 acute lymphoblastic leukemia and highlight new treatment strategies via Bcl-2 co-targeting. Oncogene. 2019;38 (17):3288-3300. doi: 10.1038/s41388-018-0670-9. PubMed PMID:30631148 .

Search PubMed

2018

  1. Veskimäe, K, Scaravilli, M, Niininen, W, Karvonen, H, Jaatinen, S, Nykter, M et al.. Expression Analysis of Platinum Sensitive and Resistant Epithelial Ovarian Cancer Patient Samples Reveals New Candidates for Targeted Therapies. Transl Oncol. 2018;11 (5):1160-1170. doi: 10.1016/j.tranon.2018.07.010. PubMed PMID:30056367 PubMed Central PMC6079561.
  2. Karvonen, H, Perttilä, R, Niininen, W, Barker, H, Ungureanu, D. Targeting Wnt signaling pseudokinases in hematological cancers. Eur J Haematol. 2018;101 (4):457-465. doi: 10.1111/ejh.13137. PubMed PMID:29989208 .
  3. Karvonen, H, Summala, K, Niininen, W, Barker, HR, Ungureanu, D. Interaction between ROR1 and MuSK activation complex in myogenic cells. FEBS Lett. 2018;592 (3):434-445. doi: 10.1002/1873-3468.12966. PubMed PMID:29292499 .

Search PubMed

Teuvo Tammela (previous Tapio Visakorpi) – Molecular Biology of Prostate Cancer
2020

  1. Bailey, MH, Meyerson, WU, Dursi, LJ, Wang, LB, Dong, G, Liang, WW et al.. Author Correction: Retrospective evaluation of whole exome and genome mutation calls in 746 cancer samples. Nat Commun. 2020;11 (1):6232. doi: 10.1038/s41467-020-20128-w. PubMed PMID:33257764 PubMed Central PMC7705717.
  2. Sipeky, C, Talala, KM, Tammela, TLJ, Taari, K, Auvinen, A, Schleutker, J et al.. Prostate cancer risk prediction using a polygenic risk score. Sci Rep. 2020;10 (1):17075. doi: 10.1038/s41598-020-74172-z. PubMed PMID:33051487 PubMed Central PMC7553910.
  3. Pakarainen, T, Nevalainen, J, Talala, K, Taari, K, Raitanen, J, Kujala, P et al.. Number of screening rounds attended and incidence of high-risk prostate cancer in the Finnish Randomized Study of Screening for Prostate Cancer (FinRSPC). Cancer. 2021;127 (2):188-192. doi: 10.1002/cncr.33254. PubMed PMID:33048394 .
  4. Hietikko, R, Kilpeläinen, TP, Kenttämies, A, Ronkainen, J, Ijäs, K, Lind, K et al.. Expected impact of MRI-related interreader variability on ProScreen prostate cancer screening trial: a pre-trial validation study. Cancer Imaging. 2020;20 (1):72. doi: 10.1186/s40644-020-00351-w. PubMed PMID:33036660 PubMed Central PMC7547469.
  5. Pöyhönen, A, Åkerla, J, Koskimäki, J, Tammela, TLJ, Auvinen, A. Seasonal changes in occurrence and severity of lower urinary tract symptoms-Tampere Aging Male Urologic Study (TAMUS). Low Urin Tract Symptoms. 2021;13 (2):216-223. doi: 10.1111/luts.12353. PubMed PMID:33034153 .
  6. Woodcock, DJ, Riabchenko, E, Taavitsainen, S, Kankainen, M, Gundem, G, Brewer, DS et al.. Prostate cancer evolution from multilineage primary to single lineage metastases with implications for liquid biopsy. Nat Commun. 2020;11 (1):5070. doi: 10.1038/s41467-020-18843-5. PubMed PMID:33033260 PubMed Central PMC7545111.
  7. Bailey, MH, Meyerson, WU, Dursi, LJ, Wang, LB, Dong, G, Liang, WW et al.. Retrospective evaluation of whole exome and genome mutation calls in 746 cancer samples. Nat Commun. 2020;11 (1):4748. doi: 10.1038/s41467-020-18151-y. PubMed PMID:32958763 PubMed Central PMC7505971.
  8. Li, CH, Prokopec, SD, Sun, RX, Yousif, F, Schmitz, N, PCAWG Tumour Subtypes and Clinical Translation et al.. Sex differences in oncogenic mutational processes. Nat Commun. 2020;11 (1):4330. doi: 10.1038/s41467-020-17359-2. PubMed PMID:32859912 PubMed Central PMC7455744.
  9. Gundem, G, Van Loo, P, Kremeyer, B, Alexandrov, LB, Tubio, JMC, Papaemmanuil, E et al.. Author Correction: The evolutionary history of lethal metastatic prostate cancer. Nature. 2020;584 (7820):E18. doi: 10.1038/s41586-020-2581-5. PubMed PMID:32728210 .
  10. Savolainen, K, Scaravilli, M, Ilvesmäki, A, Staff, S, Tolonen, T, Mäenpää, JU et al.. Expression of the miR-200 family in tumor tissue, plasma and urine of epithelial ovarian cancer patients in comparison to benign counterparts. BMC Res Notes. 2020;13 (1):311. doi: 10.1186/s13104-020-05155-6. PubMed PMID:32611374 PubMed Central PMC7329467.
  11. Siltari, A, Murtola, TJ, Talala, K, Taari, K, Tammela, TLJ, Auvinen, A et al.. Antihypertensive drug use and prostate cancer-specific mortality in Finnish men. PLoS One. 2020;15 (6):e0234269. doi: 10.1371/journal.pone.0234269. PubMed PMID:32598349 PubMed Central PMC7323967.
  12. Kohvakka, A, Sattari, M, Shcherban, A, Annala, M, Urbanucci, A, Kesseli, J et al.. AR and ERG drive the expression of prostate cancer specific long noncoding RNAs. Oncogene. 2020;39 (30):5241-5251. doi: 10.1038/s41388-020-1365-6. PubMed PMID:32555329 .
  13. Karunamuni, RA, Huynh-Le, MP, Fan, CC, Eeles, RA, Easton, DF, Kote-Jarai, Z et al.. The effect of sample size on polygenic hazard models for prostate cancer. Eur J Hum Genet. 2020;28 (10):1467-1475. doi: 10.1038/s41431-020-0664-2. PubMed PMID:32514134 PubMed Central PMC7608255.
  14. Talala, K, Heinävaara, S, Taari, K, Tammela, TLJ, Kujala, P, Stenman, UH et al.. Long-term health-related quality of life among men with prostate cancer in the Finnish randomized study of screening for prostate cancer. Cancer Med. 2020;9 (15):5643-5654. doi: 10.1002/cam4.3181. PubMed PMID:32500650 PubMed Central PMC7402814.
  15. Stuopelyte, K, Sabaliauskaite, R, Bakavicius, A, Haflidadóttir, BS, Visakorpi, T, Väänänen, RM et al.. Reply by Authors. J Urol. 2020;204 (1):77-78. doi: 10.1097/JU.0000000000000803.02. PubMed PMID:32343215 .
  16. Stuopelyte, K, Sabaliauskaite, R, Bakavicius, A, Haflidadóttir, BS, Visakorpi, T, Väänänen, RM et al.. Analysis of AR-FL and AR-V1 in Whole Blood of Patients with Castration Resistant Prostate Cancer as a Tool for Predicting Response to Abiraterone Acetate. J Urol. 2020;204 (1):71-78. doi: 10.1097/JU.0000000000000803. PubMed PMID:32068491 PubMed Central PMC7301408.
  17. PCAWG Transcriptome Core Group, Calabrese, C, Davidson, NR, Demircioğlu, D, Fonseca, NA, He, Y et al.. Genomic basis for RNA alterations in cancer. Nature. 2020;578 (7793):129-136. doi: 10.1038/s41586-020-1970-0. PubMed PMID:32025019 PubMed Central PMC7054216.
  18. Alexandrov, LB, Kim, J, Haradhvala, NJ, Huang, MN, Tian Ng, AW, Wu, Y et al.. The repertoire of mutational signatures in human cancer. Nature. 2020;578 (7793):94-101. doi: 10.1038/s41586-020-1943-3. PubMed PMID:32025018 PubMed Central PMC7054213.
  19. Rheinbay, E, Nielsen, MM, Abascal, F, Wala, JA, Shapira, O, Tiao, G et al.. Analyses of non-coding somatic drivers in 2,658 cancer whole genomes. Nature. 2020;578 (7793):102-111. doi: 10.1038/s41586-020-1965-x. PubMed PMID:32025015 PubMed Central PMC7054214.
  20. Gerstung, M, Jolly, C, Leshchiner, I, Dentro, SC, Gonzalez, S, Rosebrock, D et al.. The evolutionary history of 2,658 cancers. Nature. 2020;578 (7793):122-128. doi: 10.1038/s41586-019-1907-7. PubMed PMID:32025013 PubMed Central PMC7054212.
  21. Li, Y, Roberts, ND, Wala, JA, Shapira, O, Schumacher, SE, Kumar, K et al.. Patterns of somatic structural variation in human cancer genomes. Nature. 2020;578 (7793):112-121. doi: 10.1038/s41586-019-1913-9. PubMed PMID:32025012 PubMed Central PMC7025897.
  22. ICGC/TCGA Pan-Cancer Analysis of Whole Genomes Consortium. Pan-cancer analysis of whole genomes. Nature. 2020;578 (7793):82-93. doi: 10.1038/s41586-020-1969-6. PubMed PMID:32025007 PubMed Central PMC7025898.
  23. Cortés-Ciriano, I, Lee, JJ, Xi, R, Jain, D, Jung, YL, Yang, L et al.. Comprehensive analysis of chromothripsis in 2,658 human cancers using whole-genome sequencing. Nat Genet. 2020;52 (3):331-341. doi: 10.1038/s41588-019-0576-7. PubMed PMID:32025003 PubMed Central PMC7058534.
  24. Zapatka, M, Borozan, I, Brewer, DS, Iskar, M, Grundhoff, A, Alawi, M et al.. The landscape of viral associations in human cancers. Nat Genet. 2020;52 (3):320-330. doi: 10.1038/s41588-019-0558-9. PubMed PMID:32025001 PubMed Central PMC8076016.
  25. Akdemir, KC, Le, VT, Chandran, S, Li, Y, Verhaak, RG, Beroukhim, R et al.. Disruption of chromatin folding domains by somatic genomic rearrangements in human cancer. Nat Genet. 2020;52 (3):294-305. doi: 10.1038/s41588-019-0564-y. PubMed PMID:32024999 PubMed Central PMC7058537.
  26. Rodriguez-Martin, B, Alvarez, EG, Baez-Ortega, A, Zamora, J, Supek, F, Demeulemeester, J et al.. Pan-cancer analysis of whole genomes identifies driver rearrangements promoted by LINE-1 retrotransposition. Nat Genet. 2020;52 (3):306-319. doi: 10.1038/s41588-019-0562-0. PubMed PMID:32024998 PubMed Central PMC7058536.
  27. Yuan, Y, Ju, YS, Kim, Y, Li, J, Wang, Y, Yoon, CJ et al.. Comprehensive molecular characterization of mitochondrial genomes in human cancers. Nat Genet. 2020;52 (3):342-352. doi: 10.1038/s41588-019-0557-x. PubMed PMID:32024997 PubMed Central PMC7058535.
  28. Carlevaro-Fita, J, Lanzós, A, Feuerbach, L, Hong, C, Mas-Ponte, D, Pedersen, JS et al.. Cancer LncRNA Census reveals evidence for deep functional conservation of long noncoding RNAs in tumorigenesis. Commun Biol. 2020;3 (1):56. doi: 10.1038/s42003-019-0741-7. PubMed PMID:32024996 PubMed Central PMC7002399.
  29. Yakneen, S, Waszak, SM, PCAWG Technical Working Group, Gertz, M, Korbel, JO, PCAWG Consortium et al.. Butler enables rapid cloud-based analysis of thousands of human genomes. Nat Biotechnol. 2020;38 (3):288-292. doi: 10.1038/s41587-019-0360-3. PubMed PMID:32024987 PubMed Central PMC7062635.
  30. Reyna, MA, Haan, D, Paczkowska, M, Verbeke, LPC, Vazquez, M, Kahraman, A et al.. Pathway and network analysis of more than 2500 whole cancer genomes. Nat Commun. 2020;11 (1):729. doi: 10.1038/s41467-020-14367-0. PubMed PMID:32024854 PubMed Central PMC7002574.
  31. Jiao, W, Atwal, G, Polak, P, Karlic, R, Cuppen, E, PCAWG Tumor Subtypes and Clinical Translation Working Group et al.. A deep learning system accurately classifies primary and metastatic cancers using passenger mutation patterns. Nat Commun. 2020;11 (1):728. doi: 10.1038/s41467-019-13825-8. PubMed PMID:32024849 PubMed Central PMC7002586.
  32. Paczkowska, M, Barenboim, J, Sintupisut, N, Fox, NS, Zhu, H, Abd-Rabbo, D et al.. Integrative pathway enrichment analysis of multivariate omics data. Nat Commun. 2020;11 (1):735. doi: 10.1038/s41467-019-13983-9. PubMed PMID:32024846 PubMed Central PMC7002665.
  33. Cmero, M, Yuan, K, Ong, CS, Schröder, J, PCAWG Evolution and Heterogeneity Working Group, Corcoran, NM et al.. Inferring structural variant cancer cell fraction. Nat Commun. 2020;11 (1):730. doi: 10.1038/s41467-020-14351-8. PubMed PMID:32024845 PubMed Central PMC7002525.
  34. Rubanova, Y, Shi, R, Harrigan, CF, Li, R, Wintersinger, J, Sahin, N et al.. Reconstructing evolutionary trajectories of mutation signature activities in cancer using TrackSig. Nat Commun. 2020;11 (1):731. doi: 10.1038/s41467-020-14352-7. PubMed PMID:32024834 PubMed Central PMC7002414.
  35. Zhang, Y, Chen, F, Fonseca, NA, He, Y, Fujita, M, Nakagawa, H et al.. High-coverage whole-genome analysis of 1220 cancers reveals hundreds of genes deregulated by rearrangement-mediated cis-regulatory alterations. Nat Commun. 2020;11 (1):736. doi: 10.1038/s41467-019-13885-w. PubMed PMID:32024823 PubMed Central PMC7002524.
  36. Bhandari, V, Li, CH, Bristow, RG, Boutros, PC, PCAWG Consortium. Divergent mutational processes distinguish hypoxic and normoxic tumours. Nat Commun. 2020;11 (1):737. doi: 10.1038/s41467-019-14052-x. PubMed PMID:32024819 PubMed Central PMC7002770.
  37. Shuai, S, PCAWG Drivers and Functional Interpretation Working Group, Gallinger, S, Stein, LD, PCAWG Consortium. Combined burden and functional impact tests for cancer driver discovery using DriverPower. Nat Commun. 2020;11 (1):734. doi: 10.1038/s41467-019-13929-1. PubMed PMID:32024818 PubMed Central PMC7002750.
  38. Sieverling, L, Hong, C, Koser, SD, Ginsbach, P, Kleinheinz, K, Hutter, B et al.. Genomic footprints of activated telomere maintenance mechanisms in cancer. Nat Commun. 2020;11 (1):733. doi: 10.1038/s41467-019-13824-9. PubMed PMID:32024817 PubMed Central PMC7002710.
  39. Granberg, KJ, Raita, A, Lehtinen, B, Tiihonen, AM, Kesseli, J, Annala, M et al.. Moderate-to-strong expression of FGFR3 and TP53 alterations in a subpopulation of choroid plexus tumors. Histol Histopathol. 2020;35 (7):673-680. doi: 10.14670/HH-18-180. PubMed PMID:31660579 .

Search PubMed

2019

  1. Eerola, SK, Santio, NM, Rinne, S, Kouvonen, P, Corthals, GL, Scaravilli, M et al.. Phosphorylation of NFATC1 at PIM1 target sites is essential for its ability to promote prostate cancer cell migration and invasion. Cell Commun Signal. 2019;17 (1):148. doi: 10.1186/s12964-019-0463-y. PubMed PMID:31730483 PubMed Central PMC6858710.
  2. Booth, N, Rissanen, P, Tammela, TLJ, Kujala, P, Stenman, UH, Taari, K et al.. Cost-effectiveness analysis of PSA-based mass screening: Evidence from a randomised controlled trial combined with register data. PLoS One. 2019;14 (11):e0224479. doi: 10.1371/journal.pone.0224479. PubMed PMID:31689326 PubMed Central PMC6830755.
  3. Granberg, KJ, Raita, A, Lehtinen, B, Tiihonen, AM, Kesseli, J, Annala, M et al.. Moderate-to-strong expression of FGFR3 and TP53 alterations in a subpopulation of choroid plexus tumors. Histol Histopathol. 2020;35 (7):673-680. doi: 10.14670/HH-18-180. PubMed PMID:31660579 .
  4. Santala, EEE, Kotsar, A, Veitonmäki, T, Tammela, TLJ, Murtola, TJ. Risk of urothelial cancer death among people using antihypertensive drugs-a cohort study from Finland. Scand J Urol. 2019;53 (4):185-192. doi: 10.1080/21681805.2019.1634147. PubMed PMID:31250699 .
  5. Kinnunen, PTT, Murtola, TJ, Talala, K, Taari, K, Tammela, TLJ, Auvinen, A et al.. Anticoagulants and cancer mortality in the Finnish randomized study of screening for prostate cancer. Cancer Causes Control. 2019;30 (8):877-888. doi: 10.1007/s10552-019-01195-x. PubMed PMID:31209595 .
  6. Carlsson, SV, Månsson, M, Moss, S, Kwiatkowski, M, Recker, F, Tammela, TLJ et al.. Could Differences in Treatment Between Trial Arms Explain the Reduction in Prostate Cancer Mortality in the European Randomized Study of Screening for Prostate Cancer?. Eur Urol. 2019;75 (6):1015-1022. doi: 10.1016/j.eururo.2019.03.010. PubMed PMID:30928162 PubMed Central PMC7526685.
  7. Hugosson, J, Roobol, MJ, Månsson, M, Tammela, TLJ, Zappa, M, Nelen, V et al.. A 16-yr Follow-up of the European Randomized study of Screening for Prostate Cancer. Eur Urol. 2019;76 (1):43-51. doi: 10.1016/j.eururo.2019.02.009. PubMed PMID:30824296 PubMed Central PMC7513694.
  8. Kukko, V, Kaipia, A, Talala, K, Taari, K, Tammela, TLJ, Auvinen, A et al.. Allopurinol and the risk of prostate cancer in a Finnish population-based cohort. Prostate Cancer Prostatic Dis. 2019;22 (3):483-490. doi: 10.1038/s41391-019-0129-2. PubMed PMID:30696944 .
  9. Murtola, TJ, Sälli, SM, Talala, K, Taari, K, Tammela, TLJ, Auvinen, A et al.. Blood glucose, glucose balance, and disease-specific survival after prostate cancer diagnosis in the Finnish Randomized Study of Screening for Prostate Cancer. Prostate Cancer Prostatic Dis. 2019;22 (3):453-460. doi: 10.1038/s41391-018-0123-0. PubMed PMID:30679762 .
  10. Matejcic, M, Saunders, EJ, Dadaev, T, Brook, MN, Wang, K, Sheng, X et al.. Author Correction: Germline variation at 8q24 and prostate cancer risk in men of European ancestry. Nat Commun. 2019;10 (1):382. doi: 10.1038/s41467-019-08293-z. PubMed PMID:30655571 PubMed Central PMC6336778.
  11. Schumacher, FR, Olama, AAA, Berndt, SI, Benlloch, S, Ahmed, M, Saunders, EJ et al.. Author Correction: Association analyses of more than 140,000 men identify 63 new prostate cancer susceptibility loci. Nat Genet. 2019;51 (2):363. doi: 10.1038/s41588-018-0330-6. PubMed PMID:30622367 .
  12. Åkerla, J, Pesonen, JS, Pöyhönen, A, Häkkinen, J, Koskimäki, J, Huhtala, H et al.. Impact of lower urinary tract symptoms on mortality: a 21-year follow-up among middle-aged and elderly Finnish men. Prostate Cancer Prostatic Dis. 2019;22 (2):317-323. doi: 10.1038/s41391-018-0108-z. PubMed PMID:30410016 .
  13. Li-Sheng Chen, S, Ching-Yuan Fann, J, Sipeky, C, Yang, TK, Yueh-Hsia Chiu, S, Ming-Fang Yen, A et al.. Risk Prediction of Prostate Cancer with Single Nucleotide Polymorphisms and Prostate Specific Antigen. J Urol. 2019;201 (3):486-495. doi: 10.1016/j.juro.2018.10.015. PubMed PMID:30366021 .
  14. Pakarainen, T, Nevalainen, J, Talala, K, Taari, K, Raitanen, J, Kujala, P et al.. The Number of Screening Cycles Needed to Reduce Prostate Cancer Mortality in the Finnish Section of the European Randomized Study of Prostate Cancer (ERSPC). Clin Cancer Res. 2019;25 (2):839-843. doi: 10.1158/1078-0432.CCR-18-1807. PubMed PMID:30322875 .
  15. Murtola, TJ, Kasurinen, TVJ, Talala, K, Taari, K, Tammela, TLJ, Auvinen, A et al.. Serum cholesterol and prostate cancer risk in the Finnish randomized study of screening for prostate cancer. Prostate Cancer Prostatic Dis. 2019;22 (1):66-76. doi: 10.1038/s41391-018-0087-0. PubMed PMID:30214034 .
  16. Assel, M, Sjöblom, L, Murtola, TJ, Talala, K, Kujala, P, Stenman, UH et al.. A Four-kallikrein Panel and β-Microseminoprotein in Predicting High-grade Prostate Cancer on Biopsy: An Independent Replication from the Finnish Section of the European Randomized Study of Screening for Prostate Cancer. Eur Urol Focus. 2019;5 (4):561-567. doi: 10.1016/j.euf.2017.11.002. PubMed PMID:29137895 PubMed Central PMC5948115.

Search PubMed

2018

  1. Siltari, A, Murtola, TJ, Talala, K, Taari, K, Tammela, TLJ, Auvinen, A et al.. Antihypertensive drugs and prostate cancer risk in a Finnish population-based cohort. Scand J Urol. 2018;52 (5-6):321-327. doi: 10.1080/21681805.2018.1559882. PubMed PMID:30698056 .
  2. Schiewer, MJ, Mandigo, AC, Gordon, N, Huang, F, Gaur, S, de Leeuw, R et al.. PARP-1 regulates DNA repair factor availability. EMBO Mol Med. 2018;10 (12):. doi: 10.15252/emmm.201708816. PubMed PMID:30467127 PubMed Central PMC6284389.
  3. Åkerla, J, Pesonen, JS, Pöyhönen, A, Häkkinen, J, Koskimäki, J, Huhtala, H et al.. Impact of lower urinary tract symptoms on mortality: a 21-year follow-up among middle-aged and elderly Finnish men. Prostate Cancer Prostatic Dis. 2019;22 (2):317-323. doi: 10.1038/s41391-018-0108-z. PubMed PMID:30410016 .
  4. Matejcic, M, Saunders, EJ, Dadaev, T, Brook, MN, Wang, K, Sheng, X et al.. Germline variation at 8q24 and prostate cancer risk in men of European ancestry. Nat Commun. 2018;9 (1):4616. doi: 10.1038/s41467-018-06863-1. PubMed PMID:30397198 PubMed Central PMC6218483.
  5. Pöyhönen, A, Åkerla, J, Häkkinen, JT, Koskimäki, J, Tammela, TLJ, Auvinen, A et al.. Severity and bother of lower urinary tract symptoms among men aged 30-80 years: Tampere Ageing Male Urological Study (TAMUS). Scand J Urol. 2018;52 (4):296-301. doi: 10.1080/21681805.2018.1505944. PubMed PMID:30382800 .
  6. Rantaniemi, L, Tammela, TLJ, Kujala, P, Murtola, TJ. Blood cholesterol, tumor clinical characteristics and risk of prostate cancer progression after radical prostatectomy. Scand J Urol. 2018;52 (4):269-276. doi: 10.1080/21681805.2018.1492967. PubMed PMID:30362865 .
  7. Pakarainen, T, Nevalainen, J, Talala, K, Taari, K, Raitanen, J, Kujala, P et al.. The Number of Screening Cycles Needed to Reduce Prostate Cancer Mortality in the Finnish Section of the European Randomized Study of Prostate Cancer (ERSPC). Clin Cancer Res. 2019;25 (2):839-843. doi: 10.1158/1078-0432.CCR-18-1807. PubMed PMID:30322875 .
  8. Latonen, L, Nykter, M, Visakorpi, T. Proteomics of prostate cancer – revealing how cancer cells master their messy genomes. Oncoscience. 2018;5 (7-8):216-217. doi: 10.18632/oncoscience.453. PubMed PMID:30234142 PubMed Central PMC6142899.
  9. Murtola, TJ, Kasurinen, TVJ, Talala, K, Taari, K, Tammela, TLJ, Auvinen, A et al.. Serum cholesterol and prostate cancer risk in the Finnish randomized study of screening for prostate cancer. Prostate Cancer Prostatic Dis. 2019;22 (1):66-76. doi: 10.1038/s41391-018-0087-0. PubMed PMID:30214034 .
  10. Sipeky, C, Gao, P, Zhang, Q, Wang, L, Ettala, O, Talala, KM et al.. Synergistic Interaction of and Predisposes to Aggressive Prostate Cancer. Clin Cancer Res. 2018;24 (24):6265-6276. doi: 10.1158/1078-0432.CCR-18-0444. PubMed PMID:30181389 PubMed Central PMC6719560.
  11. Veskimäe, K, Scaravilli, M, Niininen, W, Karvonen, H, Jaatinen, S, Nykter, M et al.. Expression Analysis of Platinum Sensitive and Resistant Epithelial Ovarian Cancer Patient Samples Reveals New Candidates for Targeted Therapies. Transl Oncol. 2018;11 (5):1160-1170. doi: 10.1016/j.tranon.2018.07.010. PubMed PMID:30056367 PubMed Central PMC6079561.
  12. Gao, P, Xia, JH, Sipeky, C, Dong, XM, Zhang, Q, Yang, Y et al.. Biology and Clinical Implications of the 19q13 Aggressive Prostate Cancer Susceptibility Locus. Cell. 2018;174 (3):576-589.e18. doi: 10.1016/j.cell.2018.06.003. PubMed PMID:30033361 PubMed Central PMC6091222.
  13. Murtola, TJ, Syvälä, H, Tolonen, T, Helminen, M, Riikonen, J, Koskimäki, J et al.. Atorvastatin Versus Placebo for Prostate Cancer Before Radical Prostatectomy-A Randomized, Double-blind, Placebo-controlled Clinical Trial. Eur Urol. 2018;74 (6):697-701. doi: 10.1016/j.eururo.2018.06.037. PubMed PMID:30031572 .
  14. Kallio, HML, Hieta, R, Latonen, L, Brofeldt, A, Annala, M, Kivinummi, K et al.. Constitutively active androgen receptor splice variants AR-V3, AR-V7 and AR-V9 are co-expressed in castration-resistant prostate cancer metastases. Br J Cancer. 2018;119 (3):347-356. doi: 10.1038/s41416-018-0172-0. PubMed PMID:29988112 PubMed Central PMC6070921.
  15. Kaapu, KJ, Rantaniemi, L, Talala, K, Taari, K, Tammela, TLJ, Auvinen, A et al.. Cancer mortality does not differ by antiarrhythmic drug use: A population-based cohort of Finnish men. Sci Rep. 2018;8 (1):10308. doi: 10.1038/s41598-018-28541-4. PubMed PMID:29985440 PubMed Central PMC6037774.
  16. Dadaev, T, Saunders, EJ, Newcombe, PJ, Anokian, E, Leongamornlert, DA, Brook, MN et al.. Fine-mapping of prostate cancer susceptibility loci in a large meta-analysis identifies candidate causal variants. Nat Commun. 2018;9 (1):2256. doi: 10.1038/s41467-018-04109-8. PubMed PMID:29892050 PubMed Central PMC5995836.
  17. Schumacher, FR, Al Olama, AA, Berndt, SI, Benlloch, S, Ahmed, M, Saunders, EJ et al.. Association analyses of more than 140,000 men identify 63 new prostate cancer susceptibility loci. Nat Genet. 2018;50 (7):928-936. doi: 10.1038/s41588-018-0142-8. PubMed PMID:29892016 PubMed Central PMC6568012.
  18. Tolonen, TT, Riikonen, J, Tammela, TLJ, Koivusalo, L, Haapasalo, H, Kujala, P et al.. Extraprostatic extension (pT3a) in prostate biopsy is an under-recognized feature indicating high risk disease. Ann Diagn Pathol. 2018;35 :80-84. doi: 10.1016/j.anndiagpath.2018.06.001. PubMed PMID:29886397 .
  19. Mäkelä, VJ, Kotsar, A, Tammela, TLJ, Murtola, TJ. Bladder Cancer Survival of Men Receiving 5α-Reductase Inhibitors. J Urol. 2018;200 (4):743-748. doi: 10.1016/j.juro.2018.04.082. PubMed PMID:29730200 .
  20. Sainio, M, Visakorpi, T, Tolonen, T, Ilvesaro, J, Bova, GS. Expression of neuroendocrine differentiation markers in lethal metastatic castration-resistant prostate cancer. Pathol Res Pract. 2018;214 (6):848-856. doi: 10.1016/j.prp.2018.04.015. PubMed PMID:29728311 .
  21. Kartasalo, K, Latonen, L, Vihinen, J, Visakorpi, T, Nykter, M, Ruusuvuori, P et al.. Comparative analysis of tissue reconstruction algorithms for 3D histology. Bioinformatics. 2018;34 (17):3013-3021. doi: 10.1093/bioinformatics/bty210. PubMed PMID:29684099 PubMed Central PMC6129300.
  22. Wedge, DC, Gundem, G, Mitchell, T, Woodcock, DJ, Martincorena, I, Ghori, M et al.. Sequencing of prostate cancers identifies new cancer genes, routes of progression and drug targets. Nat Genet. 2018;50 (5):682-692. doi: 10.1038/s41588-018-0086-z. PubMed PMID:29662167 PubMed Central PMC6372064.
  23. Latonen, L, Afyounian, E, Jylhä, A, Nättinen, J, Aapola, U, Annala, M et al.. Integrative proteomics in prostate cancer uncovers robustness against genomic and transcriptomic aberrations during disease progression. Nat Commun. 2018;9 (1):1176. doi: 10.1038/s41467-018-03573-6. PubMed PMID:29563510 PubMed Central PMC5862881.
  24. Booth, N, Rissanen, P, Tammela, TLJ, Taari, K, Talala, K, Auvinen, A et al.. Costs of screening for prostate cancer: Evidence from the Finnish Randomised Study of Screening for Prostate Cancer after 20-year follow-up using register data. Eur J Cancer. 2018;93 :108-118. doi: 10.1016/j.ejca.2018.01.111. PubMed PMID:29501976 .
  25. Claessens, F, Visakorpi, T. Endocrinology of prostate cancer. Mol Cell Endocrinol. 2018;462 (Pt A):1-2. doi: 10.1016/j.mce.2018.01.005. PubMed PMID:29463415 .
  26. Ahlgren, GM, Flodgren, P, Tammela, TLJ, Kellokumpu-Lehtinen, P, Borre, M, Angelsen, A et al.. Docetaxel Versus Surveillance After Radical Prostatectomy for High-risk Prostate Cancer: Results from the Prospective Randomised, Open-label Phase 3 Scandinavian Prostate Cancer Group 12 Trial. Eur Urol. 2018;73 (6):870-876. doi: 10.1016/j.eururo.2018.01.012. PubMed PMID:29395502 .
  27. Kukko, V, Kaipia, A, Talala, K, Taari, K, Tammela, TLJ, Auvinen, A et al.. Allopurinol and risk of benign prostatic hyperplasia in a Finnish population-based cohort. Prostate Cancer Prostatic Dis. 2018;21 (3):373-378. doi: 10.1038/s41391-017-0031-8. PubMed PMID:29273728 .
  28. McNair, C, Xu, K, Mandigo, AC, Benelli, M, Leiby, B, Rodrigues, D et al.. Differential impact of RB status on E2F1 reprogramming in human cancer. J Clin Invest. 2018;128 (1):341-358. doi: 10.1172/JCI93566. PubMed PMID:29202480 PubMed Central PMC5749518.
  29. Högnäs, G, Kivinummi, K, Kallio, HML, Hieta, R, Ruusuvuori, P, Koskenalho, A et al.. Feasibility of Prostate PAXgene Fixation for Molecular Research and Diagnostic Surgical Pathology: Comparison of Matched Fresh Frozen, FFPE, and PFPE Tissues. Am J Surg Pathol. 2018;42 (1):103-115. doi: 10.1097/PAS.0000000000000961. PubMed PMID:28984675 .
  30. Murtola, TJ, Vettenranta, AM, Talala, K, Taari, K, Stenman, UH, Tammela, TLJ et al.. Outcomes of Prostate-specific Antigen-based Prostate Cancer Screening Among Men Using Nonsteroidal Anti-inflammatory Drugs. Eur Urol Focus. 2018;4 (6):851-857. doi: 10.1016/j.euf.2017.03.005. PubMed PMID:28753870 .

Search PubMed